- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Evolus Raises 2028 Revenue Targets as Toxin Market Stabilizes, Evolysse Gains Traction
Aesthetics company sees signs of improvement in botulinum toxin market and slower recovery for dermal fillers
Mar. 18, 2026 at 9:08am
Got story updates? Submit your updates here. ›
Evolus (NASDAQ:EOLS) executives reported signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers. The company outlined longer-term financial targets and recent commercial initiatives tied to its growing injectable portfolio, including the launch of its Evolysse line of hyaluronic acid fillers.
Why it matters
The aesthetics market has faced challenges in recent years, with the botulinum toxin category experiencing only a few periods of negative growth in the past 25 years. Evolus' outlook on the market stabilization and its growing injectable portfolio, including the Evolysse filler line, provide insights into the dynamics and recovery trends in this competitive industry.
The details
Evolus CEO David Moatazedi said the company is seeing improvement in the toxin market beginning in Q4 2025 and continuing into Q1 2026, with an expectation of low-single-digit market growth this year and a potential return to mid-single-digit growth by 2027-2028. The filler market has been slower to recover, which Moatazedi attributed to negative sentiment around 'overfilled' faces and a consumer preference for more natural-looking outcomes. To address this, Evolus launched its 'Drop the F Word' campaign to encourage clinics to avoid the term 'filler' in favor of 'injectable HA.' The company also highlighted the technology behind its Evolysse HA fillers, which are manufactured at near-freezing temperatures to preserve the natural HA structure.
- Evolus expects approval of its Evolysse Sculpt filler later this year.
- The company plans to launch additional filler products, including 'eyes next year' and 'lips' thereafter.
The players
Evolus
A specialty pharmaceutical company focused on medical aesthetics, headquartered in Newport Beach, California. Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures.
David Moatazedi
The CEO of Evolus.
Tatjana Mitchell
The CFO of Evolus.
Rui Avelar
The Head of R&D at Evolus.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
